Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ametis is a Russian natural-products and specialty ingredients company focused on extracting and manufacturing bioactive compounds from Dahurian larch and related plant raw materials. Its best-known commercial products are Lavitol dihydroquercetin (taxifolin) and larch arabinogalactan, which are sold into nutritional, food, pharmaceutical, cosmetic, animal husbandry, and agricultural markets. The company operates industrial-scale production rather than a traditional drug-development pipeline, and its business is centered on commercial ingredient supply and formulation support. Ametis appears to continue operating under the Ametis brand while being an acquired or parent-backed business associated with Diod.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ametis.